UBS lowered the firm’s price target on Rollins (ROL) to $58 from $62 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROL:
- Scaling a National Pest Control Platform: Rollins’s Strategic Acquisitions and Shift to ‘D2D 2.0’ Support Buy Rating
- Sotera Health appoints Kenneth Krause to board of directors
- Rollins reinstated with a Buy at BofA
- Rollins, Inc. Projects Strong Growth After Record Year
- Rollins price target lowered to $70 from $72 at Morgan Stanley